MEIP - MEI Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.06
-0.12 (-5.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.18
Open2.15
Bid2.04 x 300
Ask2.20 x 1000
Day's Range2.05 - 2.16
52 Week Range1.52 - 3.26
Volume57,830
Avg. Volume85,024
Market Cap76.328M
Beta1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.54
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.63
Trade prices are not sourced from all markets
  • MEI Pharma To Present at Two Upcoming Investor Conferences
    PR Newswirelast month

    MEI Pharma To Present at Two Upcoming Investor Conferences

    A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma's website at http://www.meipharma.com, or by following the links below in your web browser. An archived replay of each webcast will be available on MEI Pharma's website for at least 30 days after the live event concludes. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

  • MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors
    PR Newswire2 months ago

    MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors

    SAN DIEGO, Feb. 26, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Frederick W. Driscoll to its board of directors. Mr. Driscoll will serve on the audit committee. "As an industry veteran, Fred brings MEI a tremendous amount of industry and financial experience that we can leverage to effectively advance our oncology pipeline as our programs move into later stage development," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma.

  • MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer
    PR Newswire2 months ago

    MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer

    SAN DIEGO, Feb. 13, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that a planned interim review of data supports continuation of its multicenter, investigator sponsored, study evaluating ME-344, a novel mitochondrial inhibitor, in patients with HER2-negative breast cancer. The interim study data show that ME-344 was generally well-tolerated and, consistent with previous preclinical data, demonstrate the potential to reverse resistance to antiangiogenic therapy. Based on the interim results, it was determined that completion of enrollment of the clinical study of ME-344 in combination with bevacizumab (marketed as Avastin®) is warranted.

  • MEI Pharma Reports Second Quarter Fiscal Year 2018 Results
    PR Newswire2 months ago

    MEI Pharma Reports Second Quarter Fiscal Year 2018 Results

    Pipeline advancement continues, including clearance of voruciclib IND by FDA and pracinostat Orphan Drug Designation by EMA Data readouts in three programs expected in the second quarter of 2018 SAN DIEGO ...

  • PR Newswire3 months ago

    Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)

    LUGANO, Switzerland and SAN DIEGO, Jan. 11, 2018 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to pracinostat, an investigational drug candidate currently in a Phase 3 study in combination with azacitidine for the treatment of acute myeloid leukemia (AML) in adult patients unfit to induction chemotherapy.

  • MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
    PR Newswire3 months ago

    MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib

    SAN DIEGO, Jan. 8, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug Application (IND) for voruciclib, an orally available Cyclin Dependent Kinase 9 (CDK9) inhibitor, for patients with relapsed/refractory B-cell malignancies. "Inhibiting the function of certain CDK family members has shown significant clinical activity in breast cancer.

  • Capital Cube4 months ago

    ETFs with exposure to MEI Pharma, Inc. : December 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MEI Pharma, Inc. Here are 5 ETFs with the largest exposure to MEIP-US. Comparing the performance and risk of MEI Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
    PR Newswire4 months ago

    MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports

    SAN DIEGO, Dec. 21, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that a study of voruciclib, an orally available CDK9 inhibitor, was published in the journal Nature Scientific Reports. Researchers found that voruciclib when combined with the BCL-2 inhibitor Venclexta™ (venetoclax) was capable of inhibiting two master regulators of drug resistance, MCL-1 and BCL-2, and achieved synergistic antitumor efficacy in an aggressive subset of Diffuse Large B-cell Lymphoma (DLBCL). "As an orally available CDK9 inhibitor with a favorable pharmacokinetic profile and the ability to regulate MCL-1 expression, voruciclib is an ideal candidate to test in combination with a BCL-2 inhibitor such as venetoclax in patients with high risk hematological malignancies," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma.

  • MEI Pharma to Host Annual Meeting of Stockholders
    PR Newswire5 months ago

    MEI Pharma to Host Annual Meeting of Stockholders

    SAN DIEGO, Nov. 22, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 9:00 a.m. Pacific time on Thursday, November 30, 2017, at the Company's headquarters, located at 3611 Valley Centre Drive, Suite 500, San Diego, CA 92130.  Stockholders of record at the close of business on October 4, 2017 are entitled to receive notice of and vote at the Annual Meeting. A live webcast of the meeting will be accessible at www.meipharma.com.

  • MEI Pharma Reports First Quarter Fiscal Year 2018 Results
    PR Newswire5 months ago

    MEI Pharma Reports First Quarter Fiscal Year 2018 Results

    Quarter highlighted by dosing of first patient in pivotal Phase 3 study of pracinostat and exclusive license agreement for voruciclib Multiple key milestones lined up for year ahead SAN DIEGO , Nov. 8, ...

  • MEI Pharma to Present at Stifel 2017 Healthcare Conference
    PR Newswire6 months ago

    MEI Pharma to Present at Stifel 2017 Healthcare Conference

    SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 11:00 a.m. Eastern Time from the Lotte New York Palace hotel. A live webcast of the presentation can be accessed at www.meipharma.com.

  • Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session
    Zacks6 months ago

    Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session

    Aurinia Pharmaceuticals saw its shares rise nearly 8% on the day.

  • PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher
    Zacks7 months ago

    PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher

    PTC Therapeutics, Inc. (PTCT) saw its shares rise nearly 15% on the day.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of MEIP earnings conference call or presentation 5-Sep-17 1:00pm GMT

    Full Year 2017 MEI Pharma Inc Earnings Call

  • GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher
    Zacks7 months ago

    GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher

    GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares rise more than 9% on the day amid huge volumes.

  • ACCESSWIRE7 months ago

    Earnings Review and Free Research Report: MEI Pharma Reported its Full Year FY17 Results

    LONDON, UK / ACCESSWIRE / September 26, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on MEI Pharma, Inc. (NASDAQ: MEIP ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=MEIP ...

  • PR Newswire7 months ago

    MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference

    SAN DIEGO, Sept. 19, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 3:25 p.m. Eastern time from the InterContinental New York Barclay Hotel. A live webcast of the presentation can be accessed at www.meipharma.com.

  • ACCESSWIRE7 months ago

    Featured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine Patients

    Research Desk Line-up: MEI Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Teva ...

  • Zogenix, Inc. (ZGNX) Jumps: Stock Rises 5.2%
    Zacks7 months ago

    Zogenix, Inc. (ZGNX) Jumps: Stock Rises 5.2%

    Zogenix, Inc. (ZGNX) was a big mover last session, as the company saw its shares rise over 5% on the day.

  • MEI Pharma-Presage Biosciences on License Deal for Voruciclib
    Zacks8 months ago

    MEI Pharma-Presage Biosciences on License Deal for Voruciclib

    MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.

  • PR Newswire8 months ago

    MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor

    SAN DIEGO and SEATTLE, Sept. 5, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it has entered into a license agreement with Presage Biosciences, Inc. for voruciclib, a clinical-stage, oral and selective cyclin-dependent kinase (CDK) inhibitor. Under the terms of the agreement, MEI Pharma receives exclusive worldwide rights to develop, manufacture and commercialize voruciclib.

  • MEI Pharma Reports Fiscal Year 2017 Results
    PR Newswire8 months ago

    MEI Pharma Reports Fiscal Year 2017 Results

    Company Begins New Fiscal Year with $53.6 Million in Cash Clinical Progress Highlighted by Initiation of Pivotal Study for Pracinostat, Emerging Response and Safety Data for ME-401 Management Team to Host ...